These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36543976)

  • 1. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
    Kumar R; Sena LA; Denmeade SR; Kachhap S
    Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
    Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
    Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
    Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
    Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
    Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
    Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
    Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
    Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
    Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.
    Caramella I; Dalla Volta A; Bergamini M; Cosentini D; Valcamonico F; Berruti A
    Endocrine; 2022 Dec; 78(3):441-445. PubMed ID: 35986139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bipolar androgen therapy (BAT): A patient's guide.
    Denmeade S; Antonarakis ES; Markowski MC
    Prostate; 2022 May; 82(7):753-762. PubMed ID: 35357024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Denmeade S; Lim SJ; Isaaccson Velho P; Wang H
    Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
    J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
    Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
    J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
    Denmeade SR; Isaacs JT
    Prostate; 2010 Oct; 70(14):1600-7. PubMed ID: 20607766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline
    Berger BT; Labriola MK; Antonarakis ES; Armstrong AJ
    BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36653039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
    Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
    Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.